Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin plus Coenzyme Q10 in Refractory Rheumatoid Arthritis
ChiCTR-IPR-17010325Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Shanxi Medical University
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of metformin and coenzyme q10 in Refractory rheumatoid arthritis (RRA) (3 arms), sponsored by The Second Hospital of Shanxi Medical University. Primary endpoint: Efficacy endpoint. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
metformincoenzyme q10
03
Conditions
Refractory rheumatoid arthritis (RRA)
Beyond the preview
Go deeper on ChiCTR-IPR-17010325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010325.